Clinical Trials Browser

Phase 2 × Has results × olaparib × Clear all

NCT02893917 2026-03-18

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2 Active not recruiting

90 enrolled 19 charts

Prostatic Neoplasms

NCT04034927 2026-03-18

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Phase 2 Active not recruiting

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Ovarian Neoplasms

NCT03459846 2026-01-30

BAYOU

Phase 2 Active not recruiting

154 enrolled 13 charts

Urinary Bladder Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Phase 2 Completed

36 enrolled 14 charts

Castration-Resistant Prostate Carcinoma

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03953898 2025-09-10

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Phase 2 Active not recruiting

14 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04076579 2025-08-29

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Phase 2 Completed

29 enrolled 13 charts

Sarcoma

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT04336943 2025-08-11

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Phase 2 Terminated

6 enrolled 10 charts

Biochemically Recurrent Prostate Carcinoma

NCT02974621 2025-08-03

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Active not recruiting

70 enrolled 15 charts

Glioblastoma

NCT03432897 2025-07-08

337

Phase 2 Terminated

1 enrolled 8 charts

Prostatic Neoplasms

NCT03047135 2025-06-17

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Phase 2 Active not recruiting

51 enrolled 8 charts

Prostate

NCT03787680 2025-03-28

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Prostatic Neoplasms

NCT04306367 2025-02-17

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT05501548 2025-01-29

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Phase 2 Terminated

4 enrolled 5 charts

Prostatic Neoplasms

NCT04538378 2025-01-27

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 11 charts

EndocrineThoracic

EGFR-Mutated Non-Small-Cell Lung Carcinoma

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT04951492 2025-01-01

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Phase 2 Terminated

2 enrolled 9 charts

Castration-Resistant Prostate Carcinoma

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

6 enrolled 12 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03205761 2024-10-18

COMETABreast

Phase 2 Completed

11 enrolled 20 charts

Advanced Breast Cancer

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

24 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT04377087 2024-08-20

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Phase 2 Terminated

3 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03810105 2024-04-09

A Study of Olaparib and Durvalumab in Prostate Cancer

Phase 2 Terminated

5 enrolled 4 charts

Prostatic Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

Phase 2 Completed

54 enrolled 17 charts

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Phase 2 Completed

19 enrolled 9 charts

Metastatic Urothelial Cancer

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Phase 2 Completed

158 enrolled 32 charts

Prostatic Neoplasms

NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

NCT04166435 2023-09-06

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Phase 2 Completed

11 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01063517 2023-07-20

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase 2 Completed

124 enrolled 27 charts

Gastrointestinal

Stomach Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Phase 2 Completed

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Phase 2 Completed

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

Phase 2 Completed

62 enrolled 15 charts

Ovarian Neoplasms

NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

Phase 2 Completed

23 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma

NCT00628251 2019-12-05

ICEBERG 3

Phase 2 Completed

97 enrolled 22 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT01583543 2017-05-19

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Phase 2 Completed

12 enrolled 7 charts

Neoplasm Metastasis, Recurrence, Sarcoma, Ewing

NCT00912743 2016-11-09

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Phase 2 Completed

33 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms